660 results
P
individuals who developed long-term disabilities after chikungunya virus (CHIKV) disease
I/C
follow up time interval and its associated risk factors, gender, age, diabetes, hypertension, severity of pain at acute stage
O
long-term disabilities after CHIKV disease
P
patients with moderate to very severe COPD
I/C
triple inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2 agonist, ICS/LABA dual combinations
O
exacerbation rate per patient per year, changes from baseline in pre-dose trough forced expiratory volume in 1 s (FEV1)
P
children and adolescents
I/C
COVID-19, long COVID
O
increased risk
P
patients with schizophrenia
I/C
antipsychotics, non-users
O
long-term mortality
P
growing children
I/C
posterior crossbite correction, long-term stability
O
relapse of posterior crossbite
P
adults who underwent spine surgery
I/C
opioid use, preoperative opioid users, participants with preexisting depression and/or anxiety, males
O
long-term postoperative opioid use
P
long COVID-19 patients
I/C
sleep assessment, pooled prevalence of sleep disturbance
O
46%
P
older people, people with dementia
I/C
long-term care, prevalence of malnutrition
O
26.98%
P
children with short stature
I/C
weekly long-acting growth hormone replacement therapy, daily growth hormone
O
height standard deviation scores chronological age, insulin-like growth factor binding protein-3, height velocity, height standard deviation scores bone age, insulin-like growth factor 1 standard deviation scores, incidence of adverse events
P
70,273
I/C
long-term high intake of whole grains, fruits and vegetables, nuts, red/processed meat
O
cardiovascular mortality